Our Mission
The Longevity Biotechnology Association is a global non-profit organization, composed of a network of longevity biotech companies, pharmaceuticals, researchers, and investors. Our mission is to set industry standards, educate stakeholders and collaborate to translate geroscience to prevent the diseases associated with aging and extend health span.
Our Vision
LBA envisions a world where health regulatory bodies recognize that aging is the primary driver for most diseases (geroscience). Accordingly, the LBA would like the currently identified aging pathways to be targeted by recognized therapeutic solutions. Gerotherapeutics need to be recognized as beneficial to society and should be made available to all of humanity.
Human life expectancy has nearly doubled since 1900 thanks to medicine's
immense progress against
infectious diseases.
However, a consequence is that the diseases of aging have replaced infectious diseases as humanity's leading cause of death.
After decades of failure to eliminate any major age-related disease, new insights into the way the human body changes as we age have led to unprecedented optimism concerning foreseeable treatment for today's most pressing conditions.
Geroscientists have devised hundreds of interventions that can extend the healthy lifespan of animals in laboratory studies.
These interventions have now started to leave the lab bench and make their way into the clinic, shepherded by a diverse group of scientists, physicians, drug developers, businesspeople, investors, and patients.
It’s therefore timely that the leading stakeholders in this emerging sector have come together to form the
Longevity Biotechnology Association, with the following goals:
